Literature DB >> 22677730

Oncolytic viruses: a new paradigm for treatment of head and neck cancer.

John Bryan Lott1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22677730     DOI： 10.1016/j.tripleo.2011.05.021

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


× No keyword cloud information.
  3 in total

1.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report.

Authors:  Guna Proboka; Agnija Rasa; Evija Olmane; Sergejs Isajevs; Andra Tilgase; Pēteris Alberts
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.

Authors:  Yang Liu; Jing Cai; Wenfeng Liu; Yuan Lin; Li Guo; Xincheng Liu; Zhen Qin; Cuiying Xu; Yanming Zhang; Xingwen Su; Kai Deng; Guangmei Yan; Jiankai Liang
Journal:  Cell Death Dis       Date:  2020-12-12       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.